Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.230
-0.010-0.11%
Volume:59.56M
Turnover:549.93M
Market Cap:106.35B
PE:23.29
High:9.320
Open:9.130
Low:9.110
Close:9.240
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.46
T/O Rate:0.52%
Dividend:0.29
Dividend Rate:3.14%
EPS(LYR):0.396
ROE:20.90%
ROA:10.70%
PB:2.42
PE(LYR):23.29
PS:2.91

Loading ...

CSPC Pharmaceutical Starts Phase 2 Trial of Hypertension Drug

MT Newswires Live
·
Jul 30

Movement Alert|CSPC PHARMA Falls 3.2% in Regular Trading, Trading at 8.47 HKD

Market Focus
·
Jul 30

CSPC Pharma Initiates First Chinese Site for Phase II Trial of siRNA Hypertension Therapy SYH2062

Bulletin Express
·
Jul 29

CSPC PHARMA: FDA Clears Registrational Trial of Nectin-4 ADC CRB-701 for Second-Line Oropharyngeal Cancer

Bulletin Express
·
Jul 29

CSPC Pharma's CRB-701 (SYS 6002) Gets FDA Nod for Phase 2 Trial in Oropharyngeal Cancer

Stock News
·
Jul 29

CSPC Says FDA Clears Crb-701 Pivotal Trial in Second-line Oropharyngeal Cancer

Reuters
·
Jul 29

CSPC Pharmaceutical - Crb-701 Receives FDA Clearance for Registrational Trial in Second-Line Oropharyngeal Cancer

THOMSON REUTERS
·
Jul 29

CSPC Pharmaceutical Group Stock Rallies 3.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 29

Movement Alert|CSPC PHARMA Rises 3.06% in Regular Trading, Mid-Term Profit Alert and Multiple Pipeline Catalysts Continue to Ferment

Market Focus
·
Jul 29

Citi Reaffirms Buy Rating on CSPC Pharma, Sets Price Target at HK$11.50

Deep News
·
Jul 29

Citi: CSPC Pharma's (01093) Interim Profit Alert Far Exceeds Expectations, 'Buy' Rating Reaffirmed

Stock News
·
Jul 28

China's CSPC Pharmaceutical Rises on Robust H1 Earnings Forecast

Reuters
·
Jul 28

CSPC Pharma's Depression Drug Meets Primary Endpoint in Phase 3 Trial

MT Newswires Live
·
Jul 28

CSPC Pharma's Sirolimus Drug Application Accepted in China

MT Newswires Live
·
Jul 28

Movement Alert|CSPC PHARMA Rises 3.86% in Regular Trading, Interim Profit Forecast Surges as Antidepressant Drug Phase III Trial Hits Primary Endpoint

Market Focus
·
Jul 28

Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street

Stock News
·
Jul 28

Cspc Pharmaceutical Says Phase III Trial of Ha1406 Meets Primary Endpoint

Reuters
·
Jul 27

CSPC PHARMA's Injectable Sirolimus (Albumin-Bound) New Drug Application Accepted by China's NMPA

Stock News
·
Jul 27

CSPC Pharma: Ammoxetine (HA1406) Clears Phase III with Statistically Significant Efficacy in Depression

Bulletin Express
·
Jul 27

CSPC Says China NMPA Accepts Sirolimus Albumin-bound Injection Filing, Grants Priority Review

Reuters
·
Jul 27